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Background. Cholesteatoma is a destructive process of the middle ear resulting in erosion of the surrounding bony structures
with consequent hearing loss, vestibular dysfunction, facial paralysis, or intracranial complications. The etiopathogenesis of
cholesteatoma is controversial but is associated with recurrent ear infections. The role of intracellular innate immune receptors,
the NOD-like receptors, and their associated signaling networks was investigated in cholesteatoma, since mutations in NOD-like
receptor-related genes have been implicated in other chronic inflammatory disorders. Results. The expression of NOD2 mRNA
and protein was significantly induced in cholesteatoma compared to the external auditory canal skin, mainly located in the
epithelial layer of cholesteatoma. Microarray analysis showed significant upregulation for NOD2, not for NOD1, TLR2, or TLR4
in cholesteatoma. Moreover, regulation of genes in an interaction network of the NOD-adaptor molecule RIPK2 was detected.
In addition to NOD2, NLRC4, and PYCARD, the downstream molecules IRAK1 and antiapoptotic regulator CFLAR showed
significant upregulation, whereas SMAD3, a proapoptotic inducer, was significantly downregulated. Finally, altered regulation
of inflammatory target genes of NOD signaling was detected. Conclusions. These results indicate that the interaction of innate
immune signaling mediated by NLRs and their downstream target molecules is involved in the etiopathogenesis and growth of
cholesteatoma.
1. Introduction
Cholesteatomas are squamous epidermal lesions that develop
in the middle ear spaces and promote erosion of the sur-
rounding bony structures. This can lead to hearing loss,
vertigo, facial palsy, or intracranial complications such as
meningitis or brain abscess. It has been hypothesized that
the development of cholesteatoma involves altered control
of cellular proliferation, leading to aggressive and invasive
growth of the squamous epithelium, after an inflammatory
stimulus [1]. Acquired cholesteatomas are often associated
with recurrent or persistent otitis media, and they often
contain bacteria.
The innate immune system serves as the first line of
defense against invading pathogens and has been increasingly
associated with inflammatory processes of the middle ear.
Cells of the middle ear mucosa (MEM) express var-
ious pattern recognition receptors (PRRs) that interact
with pathogens or pathogen associated molecular pat-
terns (PAMPs) regulating the expression of inflammatory
cytokines, interferons, and antimicrobial peptides [2]. Some
PRRs are also involved in the regulation of apoptosis and
mediate innate resistance mechanisms against intracellular
microbes [3–5]. A very important family of PRRs is the
Toll-like receptors (TLRs) [2]. The expression of TLR 2, 3,
and 4 has been demonstrated in the microenvironment of
human acquired cholesteatoma [6]. Recently, we identified
genes of the TLR-family whose absence led to development
of persistent otitis media in an otherwise self-limitingmurine
model of otitis media and in cholesteatoma [7–10]. A clinical
association between polymorphisms in TLRs, the TLR4
coreceptor CD14, and tumor necrosis factor 𝛼 (TNF𝛼) has
Hindawi Publishing Corporation
BioMed Research International
Volume 2015, Article ID 408169, 9 pages
http://dx.doi.org/10.1155/2015/408169
2 BioMed Research International
been described in childrenwith recurrent otitismedia [11, 12].
Taken together, these data indicate that the innate immune
system plays not only a significant role in otitis media but
in cholesteatoma. However, there are additional receptors
that play important roles in innate immunity. The NOD-like
receptors (NLRs) are a family of cytosolic proteins involved
in the recognition of intracellular pathogens [13]. Promi-
nent members include nucleotide-binding oligomerization-
domain protein 1 (NOD1) and NOD2, which contain a cas-
pase recruitment domain (CARD), a nucleotide-binding and
oligomerization domain (NOD), and leucine-rich repeats.
NOD2 sense muramyl dipeptides (MDPs) via their leucine-
rich repeat domains [13–15]. MDPs are elements of the
bacterial cell wall common to both gram-positive and gram-
negative bacteria.
The TLR and NLR families can interact in the response to
PAMPs. For example, peptidoglycan (PGN) fraction poten-
tially activates both cell-surface TLR2 and cytosolic NODs
through the generation of muramyl dipeptide (MDP) [16].
Simultaneous activation ofNOD2 byMDP leads to activation
of RICK by NOD2 and the downmodulation of the TLR2-
signaling pathway [16].
Activation of NLRs causes transcription of proinflam-
matory cytokines, defensins, and chemokines via the adap-
tor molecule RIPK2 (receptor-interacting serine/threonine-
protein kinase 2) and a pathway leading to NF𝜅B [17–19]. In
epithelial and stromal cells, NOD1-dependent production of
pathogen-induced IL1𝛽 (interleukin-1 beta) and chemokines
such as CXCL8/IL8, CCL2/MCP-1, CXCL2/MCP-2, and
CCL1/MIP-2 has been described [20].These chemokines play
a major role in local macrophage and neutrophil recruitment
during the initial stages of inflammation. For example,
Lysenko and colleagues demonstrated that NOD1 is cru-
cial to neutrophil-mediated clearance of bacterial infection
in vivo and that opsonophagocytic killing of bacteria in
vitro is significantly reduced in NOD1-deficient neutrophils
[21]. Similarly, neutrophils lacking NOD2 exhibit deficient
cytokine and chemokine production [22]. Mutations of the
NLR genes have also been described in the context of several
chronic inflammatory diseases, such as Crohn’s disease or
Blau syndrome [15, 23].
The role of NLR signaling on cholesteatoma has not
been well studied, although a recent study documented
enhanced levels of NOD2 mRNA [24]. Our study evaluates
the expression profiles and a completeNLR signaling network
in cholesteatoma based on an altered regulation of multiple
NOD-related signaling genes in cholesteatoma tissue derived
from patients undergoing middle ear surgery. We demon-
strate that NLR signaling gene networks and target genes are
differentially regulated in this tissue consistent with a role in
the etiopathogenesis of acquired cholesteatoma.
2. Methods
2.1. Human Samples. After informed consent was obtained,
samples of acquired cholesteatoma and normal external audi-
tory canal skin (EAS) samples were obtained from patients
undergoing middle ear surgery at the ENT Departments,
University of Luebeck and Klinikum Bielefeld (Germany).
All samples (cholesteatoma 𝑁 = 64 and skin 𝑁 = 64)
were immediately stored in liquid nitrogen and prepared
as described elsewhere [10]. This protocol was approved by
the Ethical Review Committees at Luebeck University and
Ruhr University of Bochum. All clinical investigations were
conducted according to the principles of the Declaration of
Helsinki (1964).
2.2. Quantification by Real-Time PCR. The protocol for real-
time quantitative PCR is identical with that used in previously
published work by our group [10]. Total RNA was extracted
from cholesteatoma (𝑁 = 10) and skin biopsies (𝑁 = 10),
using RNeasy Mini Kits (Qiagen, Mississauga, ON, Canada).
The amount of RNA was measured by spectrophotometer.
According to the manufacturer’s protocol, 0.5 𝜇g of total
RNA was converted to cDNA using the First Strand cDNA
Synthesis Kit (Fermentas, St.Leon-Rot, Germany). Following
reverse transcription (RT) reaction, all samples were diluted
1 : 4 in ddH
2
O and subjected to real time PCR analysis
with Maxima SYBR Green QPCR Master Mix (Fermentas,
St. Leon-Rot, Germany). 0.3 𝜇M of gene specific primers
(TNF, NOD1, NOD2, and GAPDH, Eurofins MWG Operon,
Ebersberg) was used in a total reaction volume of 25𝜇L. For
all targets, the cycling conditions were 50∘C for 2 minutes,
95∘C for 10 minutes, followed by 40 cycles each consisting
of 95∘C for 15 seconds, 60∘C for 30 seconds, and 72∘C
for 30 seconds. Integration of SYBR Green dye into the
PCR products was monitored using the ABI PRISM 7000
Sequence Detection System (Applied Biosystems, Carlsbad,
CA, USA). The Pfaffl analysis method was used to measure
the relative quantity of gene expression [25].The specificity of
amplified PCR products was confirmed by dissociation curve
analysis (SDS software 1.1, Applied Biosystems).The reference
gene, GAPDH, was selected based on its stable expression
in all tissues analyzed. All measurements were performed in
triplicate and three independent experiments were executed
for each gene target.
2.3. Immunohistochemistry. Tissue sections were fixed using
4% paraformaldehyde (PFA) for 60 minutes at 4∘C followed
by 3 wash steps in phosphate buffered saline (PBS) of 5
minutes each. Blocking was performed in 5% goat serum for
30 minutes followed by incubation with primary antibodies
for 2 hours at room temperature at the following dilu-
tions: rabbit anti-NOD1 1 : 500 (Sigma-Aldrich) and rabbit
anti-NOD2 1 : 500 (Sigma-Aldrich). Secondly, fluorochrome-
conjugated antibodies were diluted 1 : 300 (Alexa 555) and
slices were incubated for 1 hour at room temperature within
this solution. Nuclear counterstaining was performed using
SYTOX green, 1 : 20000 (Molecular Probes) for 30 minutes at
room temperature. The stained sections were mounted with
Mowiol (Carl Roth) and dried over night at 4∘C. Fluorescence
imaging was performed using a confocal microscope (LSM
510, Carl Zeiss, San Diego, CA, USA, and DM IRB, Leica
Microsystems, Inc., Buffalo Grove, IL, USA).
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For LSAB (Labeled(Strep)Avidin-Biotin) staining paraf-
fin-embedded, formalin-fixed tissue sections were deparaffi-
nized and rehydrated in xylene, ethanol, and TBS. Endoge-
nous peroxidases (15min incubation in 3% H
2
O
2
) and
endogenous biotin (Avidin/Biotin Blocking Kit, Vector Labo-
ratories, Burlingame, CA)were blocked. For antigen retrieval,
sections were incubated in Proteinase K (DAKO, Carpinteria,
CA) for 7min, blocked with 1% BSA in PBS and incu-
bated with anti-Nod2 (1 : 600, Santa Cruz, sc 56168) primary
antibody in PBS overnight, 0.1% BSA, washed in PBS and
detected withHRP anti-rabbit secondary antibodies (DAKO)
and AEC peroxidase substrate kit (Vector Laboratories)
according to the manufacturers’ instructions.
2.4. RNA Amplification Labeling and Hybridization to Agi-
lent Microarrays. The procedure for microarray analysis
was described earlier by our group [10]. The commercially
available Whole Human Genome (4 × 44) Oligo Microarray
(Agilent Technologies, Santa Clara, CA, USA) was used in
this study according to the instructions of the manufacturer.
RNA was extracted from cholesteatoma (𝑁 = 17) and
external auditory canal skin (𝑁 = 17) using RNasy Mini
Kits (Qiagen, Mississauga, ON, Canada) according to the
manufacturer’s instructions. 500 ng of the purified total RNA
was subjected to T7-based amplifications using Agilent Amp
Labeling Kit to generate fluorescent cRNA. The method uses
T7 RNA polymerase, which at the same time amplifies target
material and incorporates cyanine 3- or cyanine 5-labeled
CTP. Hybridization to whole human genome microarray
gene expression chips (Agilent Technologies, Inc.) and dye
swaps (Cy3 and Cy5) were performed for RNA, ampli-
fied from each specimen. Microarray chips were washed
and immediately scanned using a high resolution Agilent©
microarray scanner G2565CA (Agilent Technologies, Inc.).
For microarray processing, different Bioconductor soft-
ware packages were used (Bioconductor, Open Source Soft-
ware for Bioinformatics). Primarily, the LIMMA (Linear
Models for Microarray Data) [26] package was included in
an in-house R-analysis pipeline that uses linearmodels for the
analysis of experiments and assessment of differential expres-
sion. Its capabilities were used to analyze and investigate the
two-color spotted arrays and the two channel microarray
experiments.
Microarray data discussed in this publication have been
deposited in NCBI’s Gene Expression Omnibus and are
accessible through GEO Series accession number GSE42256
[10].
2.5. Bioinformatical Network Analysis. The procedure for
network analysis was also described earlier by our group
[10]. We used an in-house open-source software application
VANESA (http://www.vanesa.sf.net). VANESA is modeling
experimental results that can be expanded with database
information to perform biological network analysis [27]. In
order to broaden the scope of our model, we also used inte-
grated databases such as HPRD, IntAct, and MINT to obtain
information of interest and aid in network reconstruction.
HPRD is a database of curated proteomic information
pertaining to human proteins [28].The information provided
in the database is experimentally derived, based on mass
spectrometry, protein-microarray, protein-protein interac-
tion, posttranslational modifications (PTMs), and tissue
expression. A further resource for protein-protein interaction
data is the IntAct database [29]. IntAct provides data curated
from literature as well as direct data deposits. Primarily, it
consists of protein-protein interaction data. However, it also
includes protein-small molecules for other organisms, such
as Rattus norvegicus. The Molecular Interaction Database
MINT [30] was also queried as it contains approximately
235,000 interactions from over 4,800 publications. MINT
contains interactions from more than 30 different species
and provides 28,283 interactions for Homo sapiens, 4,808 for
Mus musculus, and 2,804 entries for Rattus norvegicus, which
are of great value. A detailed approach of the bioinformatic
network analysis based on the mentioned data sources will
be published elsewhere (Janowski et al., in preparation).
2.6. Statistics. ANOVA was performed using StatView and
GraphPad Prism software as described elsewhere [7, 8].
Differences between groups were considered significant at
𝑃 < 0.05.
3. Results
3.1. NOD2 Gene Expression Is Upregulated in Cholesteatoma.
Real-time PCR (QPCR) data indicated that the mRNA
expression of NOD2 was significantly increased in
cholesteatoma compared to EAS (Figure 1). NOD1 expression
was slightly elevated compared to samples of the EAS but
was not significantly regulated.
3.2. NOD1 and NOD2 Protein Expression in Cholesteatoma
Tissue. To evaluate the translation and localization of the
NLRs in human samples of cholesteatoma, the receptors
were labeled on cryosections using anti-NOD1 (Sigma-
Aldrich) or anti-NOD2 (Sigma-Aldrich) antibodies. Figure 2
demonstrates the expression of NOD1 and NOD2 protein
in cholesteatoma and in EAS. Both NOD1 as well as NOD2
protein were readily detected. Similar to the gene expression
results, NOD2 protein in cholesteatoma was visibly elevated
compared to external EAS, whereasNOD1 protein expression
showed little difference between the two tissues. Immunohis-
tochemistry also revealed that NOD1 and NOD2 were local-
ized primarily in the epithelial layers of the cholesteatoma
matrix within the stratum corneum and stratum granulosum
and lower in the basal epithelial layers (Figure 2 and Supple-
mentary Figure 1 in Supplementary Material available online
at http://dx.doi.org/10.1155/2015/408169).
3.3. Altered Regulation of NLR-Related Genes in Choles-
teatoma. The expression levels of a subset of inflamma-
tory genes known to be associated with NOD signaling
were examined in human cholesteatoma samples via whole-
genomemicroarray analysis and compared to EAS (Figure 3).
While NOD2 transcripts showed a significant upregulation
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Figure 1: NOD1 and NOD2 mRNA expression in cholesteatoma.
NOD1 (left bar) and NOD2 (right bar) mRNA expression in
cholesteatoma compared to external auditory canal skin (EAS). Real
time PCR reveals no significantly higher gene expression of NOD1
within the cholesteatoma, but a significantly higher expression of
NOD2 compared to EAS. For normalization, the housekeeping gene
GAPDH was used and compared to EAS.𝑁 = 10 samples; statistics
was performed by GraphPad Prism with the use of an unpaired 𝑡-
test, 𝑃 < 0.05.
compared to samples of external auditory skin, NOD1,
RIPK2, TLR2, or TLR4 were not significantly induced. The
genes encoding IL1𝛽, IRAK1, and p65 and the antiapoptotic
regulator cFlip/CFLAR were also significantly upregulated
compared to EAS. Furthermore, mRNA encoding IKK2 and
NGFR (Nerve Growth Factor Receptor), which has many
different roles, including stimulating cells to survive and
differentiate [31–33], were downregulated in cholesteatoma
compared to EAS samples.
3.4. Protein Interaction Networks. To further elucidate the
role of NODs in cholesteatoma, protein networks related to
NLR signaling were reconstructed based on the published
literature, high-throughput and other database information,
and computational analyses. Figure 4 presents these net-
works, with connections between proteins derived from
the IntAct, MINT, and HPR databases. Proteins for which
significant differences in gene expression noted in our array
data are indicated.
This analysis highlighted the upregulation of several
genes involved in theNODprotein network in cholesteatoma,
some of which have been noted above, including NOD2,
NLRC4, and PYCARD, the downstream molecules IRAK1
and the antiapoptotic regulator cFLAR (red). As above, there
was no regulation of NOD1 or RIPK2 (black). Interestingly,
the analysis identifies the interaction of RIPK2 with many
genes involved in inflammatory and apoptotic processes that
are differentially regulated in cholesteatoma. This included
NOD2, IRAK1, and CFLAR, which are proinflammatory and
antiapoptotic. In contrast, SMAD3, a proapoptotic inducer,
was significantly downregulated. NOD1 and many proapop-
totic caspase genes such as CASP1, CASP2, CASP8, and
CASP9 were not altered in cholesteatoma. A second network
that was regulated is that of ERBB2IP, a modulator of
EGF family member signaling through the ERBB2 (HER2)
receptor. Elements of this pathway were downregulated in
cholesteatoma when compared to EAS.
3.5. NLR Target Gene Expression Is Upregulated in Choles-
teatoma. Activation of NLR signaling networks results in the
expression of many downstream genes including cytokines
[17–19]. The expression of the downstream and effector
signaling genes TNF𝛼 and IL1𝛽 was therefore analyzed by
QPCR in human samples of cholesteatoma of the middle
ear. The samples were evaluated relative to GAPDH and
compared to normal, uninfected skin from the external ear
canal. As shown in Figure 5, the mRNA expression of TNF𝛼
and IL1𝛽 was significantly higher in cholesteatoma samples
compared to the noninvasive squamous epidermal cells of
external auditory skin (EAS).
4. Discussion
In the present study, we examined the role of NODs and
NOD signaling proteins in cholesteatoma, based on their
known ability to stimulate the expression of cytokines. To
our knowledge, we offer the first evidence for the presence of
a complete NLR signaling network in cholesteatoma, based
on an altered regulation of multiple NOD-related signaling
genes. Moreover, NOD2 itself was consistently significantly
induced compared to NOD1 and RIPK2, as investigated by
QPCR and microarray data from more than 60 patients. We
also confirmed significant upregulation of the downstream
effectormolecules TNF and IL1𝛽 in samples of cholesteatoma
compared to samples of the EAS. Enhanced expression of
additional cytokines known to be regulated by NLR signaling
has previously been described in cholesteatoma by our
group [10, 34], adding to the evidence for an NLR role in
etiopathogenesis of this disease.
Immunohistochemistry demonstrated that, while only
NOD2 was enhanced in cholesteatoma compared to EAS,
both NOD1 and NOD2 are present in cholesteatoma. This
finding suggests that NOD1 functions as a constitutively
expressed sentinel receptor in EAS, whereas additional
NOD2 is produced as needed in response to specific stimuli.
The immunolocalization of NOD proteins in the surface
epithelial layers of cholesteatoma is consistent with their role
in innate immune defense against invading organisms. In this
respect, it is important to note that bacteria and bacterial
biofilms are commonly observed prior to cholesteatoma
formation and in cholesteatomas themselves [35]. It is thus
possible that the upregulation and/or activation of NOD2
is related to the presence of bacterial PAMPs. Given the
invasive nature of cholesteatoma, tissue damage is likely
an ongoing process. This could establish a “vicious cycle”
of positive feedback, with NOD2 stimulation producing
inflammatory cytokines and tissue damage, which in turn
releases additional NOD2 ligands.
Infection often accompanies cholesteatoma and most
cytokines and receptors work together in innate immune
responses. Indeed, we found a significantly robust upreg-
ulation of the proinflammatory-related genes TNF𝛼, IL1𝛽,
IRAK1, p65, NOD2, and a downregulation of IKK2 in
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Figure 2: Localization of NOD2 and NOD1 in cholesteatoma and in external auditory canal skin (EAS). Protein expression in cholesteatoma
demonstrates a higher expression of NOD2 within the cholesteatoma compared to EAS, whereas NOD1 displays no significant change
compared to EAS. Upper column displays a positive immunofluorescence staining of NOD2 and NOD1 in EAS compared to cholesteatoma
in the lower column imaging staining, using a confocal microscope. Red represents the target genes NOD1 and NOD2 and green represents
nuclei.
Gene expression analysis cholesteatoma versus EAS
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Figure 3: Altered inflammatory gene regulation in cholesteatoma
versus EAS via microarray analysis. Significant upregulation of the
inflammatory-related genes IL1, cFlip, p65, and IRAK. Moreover,
there was a significant upregulation of the pattern recognition
receptor (PRR) NOD2, but no significant upregulation of NOD1,
TLR2, or TLR4 and the adaptor protein RIPK2. Furthermore, the
figure displays a downregulation of NGFR in cholesteatoma. Gene
expression analysis was performed via microarray analysis.
cholesteatoma. The observation of upregulated NF-𝜅B in
human cholesteatoma epithelium via immunohistochem-
istry supports our gene expression data [36]. Our observa-
tions confirm the involvement of inflammatory processes in
cholesteatoma and the interaction of several molecules of the
innate immunity triggered via pattern recognition receptors
such as NOD2 downstream to NF-𝜅B activation and induc-
tion of several cytokines such as IL1𝛽 or TNF𝛼, which work
in concert and thusmay regulate the pathogenesis and trigger
the progress of acquired cholesteatoma.
It is also important to note that elements of the ERBB2IP
signaling network, which is known to be associated with
NOD2 signaling [37], were found to be downregulated in
cholesteatoma compared to EAS. ERBB2IP binds to a phos-
phorylation site on the ERBB2 (HER2) EGF receptor, stabi-
lizing the molecule in its unphosphorylated state. ERBB2IP
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Figure 4: Bioinformatical network analysis for NOD. Proteins are the nodes and the edges are protein activations/inactivations, such as
phosphorylation and dephosphorylation across a set of proteins. The network reveals an upregulation of NOD2, NLRC4, and PYCARD and
the downstream molecules IRAK1 and cFLAR (red), whereas SMAD3 seems to be downregulated (green). TLR2, TLR4, NOD1, and RIPK2
were not significantly altered (black). RIPK2 displayed a remarkable network with many genes involved in the inflammatory and apoptotic
process within the cholesteatoma.𝑁 = 17 samples; means ± SEM; ∗𝑃 < 0.05.
also interferes with downstream activation of Ras/Raf [38].
This inhibitory action reduces the response of ERBB2 to EGF
family members and consequent cell proliferation. Inhibition
of ERBB2IPwould therefore be expected to disinhibit ERBB2,
enhancing the proliferation of epithelial cells and growth of
the cholesteatoma, which has been shown to express ERBB2
as well as several EGF family members [39].
Relative to cholesteatoma progression, the potential for
enhanced growth of cholesteatoma cells indicated by our
finding of ERBB2IP signaling downregulation was accom-
panied by enhanced expression of antiapoptotic genes, such
as cFLIP/CFLAR [40] and downregulation of the proapop-
totic inducer SMAD3 [41], which is in contrast to some
other inflammatory diseases [42]. Moreover downregulation
of NGFR in cholesteatoma might inhibit the process of
cell survival and differentiation and inhibit the cell death
restoration, which could be demonstrated in other cells
[31–33]. This would be expected to contribute to enhanced
epithelial cell proliferation and cholesteatoma growth and on
the other hand to induced cell death, loss of differentiation,
and decreased cell survival, which in fact is the nature of
a cholesteatoma mass. Moreover, while NOD1 signaling has
been linked to activation of cell death [43], NOD2 can
induce the expression of proinflammatory cytokines without
influencing apoptosis [44].Thus, the nature of NLR signaling
in cholesteatoma, with enhancement of NOD2 but not NOD1
expression, may contribute to the progressive and invasive
nature of this disease.
5. Conclusions
The results of this study indicate that the interaction of innate
immune signaling, cell proliferation, and cell survival medi-
ated by NLRs and their protein-interactions are involved in
the etiopathogenesis and regulation of cholesteatoma. Innate
immunity has also been identified as an important element in
BioMed Research International 7
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Figure 5: TNF𝛼 and Il1𝛽mRNAexpression in cholesteatoma. TNF𝛼
and Il1𝛽 mRNA expression in cholesteatoma compared to external
auditory canal skin (EAS). Real time PCR reveals a significantly
higher expression of TNF𝛼 and Il1𝛽 within the cholesteatoma com-
pared to EAS. For normalization, the housekeeping gene GAPDH
was used and compared to EAS. 𝑁 = 10 samples; statistics was
performed by GraphPad Prism with the use of an unpaired 𝑡-test,
𝑃 < 0.05.
the regulation of otitis media [45, 46], the precursor to many
cases of cholesteatoma. Therapeutic manipulation of NOD
signalingmight therefore provide an effective approach to the
treatment of this disease.
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